NTRK1 and gastrointestinal stromal tumor: Sunitinib (also known as SU11248) was developed as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, and approved by the FDA in 2006 for the treatment of renal cell carcinoma (RCC) and imatinib resistant gastrointestinal stromal tumor (GIST) [6], [7].